Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions (Details Textual)

v3.19.1
Note 4 - Acquisitions (Details Textual) - USD ($)
$ in Thousands
8 Months Ended 9 Months Ended
Aug. 01, 2018
Jul. 02, 2018
Mar. 31, 2019
Mar. 31, 2019
Mar. 31, 2019
Mar. 31, 2019
Mar. 31, 2018
Feb. 01, 2018
Jan. 02, 2018
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 272,286     $ 65,066    
QT Holdings Corporation [Member]                  
Payments to Acquire Businesses, Net of Cash Acquired, Total   $ 20,404       $ 20,461      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   51,000 $ 51,000 51,000 $ 51,000 51,000      
Goodwill, Purchase Accounting Adjustments         3,800 3,792      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   $ 20,000 12,200 12,200 12,200 12,200      
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles           (7,800)      
Atlanta Biologicals [Member]                  
Business Acquisition, Goodwill, Expected Tax Deductible Amount                 $ 0
Exosome Diagnostics, Inc [Member]                  
Payments to Acquire Businesses, Net of Cash Acquired, Total $ 251,825   251,825            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 325,000   325,000 325,000 325,000 325,000      
Business Acquisition, Goodwill, Expected Tax Deductible Amount 0                
Goodwill, Purchase Accounting Adjustments     13,474            
Exosome Diagnostics, Inc [Member] | Trade Names [Member]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   58,000 58,000 58,000 58,000      
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles     58,000            
Exosome Diagnostics, Inc [Member] | Developed Technology [Member]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 180,000   105,000 105,000 105,000 105,000      
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles     (75,000)            
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   2,300 $ 2,300 2,300 2,300      
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles     2,300            
Finite-Lived Intangible Asset, Useful Life       14 years          
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]                  
Finite-Lived Intangible Asset, Useful Life       15 years          
Exosome Diagnostics, Inc [Member] | Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 250,000                
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 45,000                
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 30,000                
Eurocell Diagnostics, SAS [Member]                  
Business Acquisition, Goodwill, Expected Tax Deductible Amount               $ 0  
Goodwill, Purchase Accounting Adjustments     13,500            
Eurocell Diagnostics, SAS [Member] | Trade Names [Member]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     58,000 $ 58,000 58,000 58,000      
Eurocell Diagnostics, SAS [Member] | Developed Technology [Member]                  
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles     (75,000)            
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     $ 2,300 $ 2,300 $ 2,300 $ 2,300